PTPRC and acute myeloid leukemia: PDX models from 105 patients (66%), including 84 with de novo AML, were successfully established, whereas the engraftment of human CD45+ cells was not confirmed in samples from the other 55 patients (34%); 28 models died within 365 days (median 270 days, range 110–364) without positive hCD45+ in PB, 18 with negative human CD45+ in PB until day 365, 7 with T-cell engraftment, and 2 failed in serial passaging with hCD45+ >5% in PB, but <20% in BM, at day 365.